Breaking Down Xi'an Manareco New Materials Co.,Ltd Financial Health: Key Insights for Investors

Xi'an Manareco New Materials (688550.SS) presents a dynamic financial picture that demands a closer look: Q3 2025 revenue reached CNY 495.11 million (up 23.78% QoQ) and trailing twelve-month sales total CNY 1.67 billion (YoY growth 21.68%), with 2024 revenue at CNY 1.46 billion (+20.74% from 2023) and revenue per employee about CNY 1.04 million across 1,608 staff; profitability surged in 2024 with net income of CNY 250.3 million (an 87% rise), a profit margin of 17%, EPS of CNY 1.44 and ROE of 10.7%, while liquidity shows CNY 807 million in cash and cash equivalents as of Q1 2025 alongside CNY 275 million receivables and CNY 484 million inventory; market valuation metrics include a market capitalization of CNY 7.81 billion, trailing P/E 22.67, forward P/E 24.25, P/S 4.69 and P/B 2.52, yet governance disputes, a rejected supervisory-board change, the May 2024 stake move by Kaikang Group, and the July 2025 termination of an API project (CNY 179 million invested by June 30, 2025) underscore material risks even as R&D investment (CNY 200 million), strategic distributor partnerships and green-technology incentives point to growth avenues-read on for the full breakdown and data-driven insights investors need to assess opportunity and risk.

Xi'an Manareco New Materials Co.,Ltd (688550.SS) - Revenue Analysis

Xi'an Manareco reported continued top-line expansion driven by product mix improvements and market demand recovery. Key revenue metrics and trends highlight both recent momentum and scale relative to workforce and market valuation.

• Q3 2025 revenue: CNY 495.11 million - up 23.78% quarter-on-quarter.
• Trailing twelve months (TTM) revenue: CNY 1.67 billion - up 21.68% year-over-year.
• 2024 full-year revenue: CNY 1.46 billion - up 20.74% from 2023.
• Revenue per employee: ~CNY 1.04 million (1,608 employees).
• Price-to-sales (P/S) ratio: 4.69.
• Market capitalization: CNY 7.81 billion.

Quarterly acceleration in Q3 2025 suggests seasonal or execution-driven pickup; TTM and annual growth rates confirm sustained expansion versus prior year.

• Implication: At a P/S of 4.69 and CNY 1.67B TTM sales, market pricing implies growth expectations; investors should weigh margin trends and capital intensity against projected revenue expansion.
• Operational note: Revenue per employee (~CNY 1.04M) indicates productivity benchmarks relative to peers in advanced materials and specialty chemicals.
• Reference for corporate direction: Mission Statement, Vision, & Core Values (2026) of Xi'an Manareco New Materials Co.,Ltd.

Xi'an Manareco New Materials Co.,Ltd (688550.SS) - Profitability Metrics

Xi'an Manareco delivered marked improvement in 2024 profitability, driven by higher revenue and operational leverage. Key headline figures and trend context are presented below.

• Net income (2024): CNY 250.3 million - +87% year-over-year.
• Profit margin (2024): 17.0% (vs. 11.0% in 2023).
• Earnings per share (EPS, 2024): CNY 1.44 (2023: CNY 0.75).
• Return on equity (ROE): 10.7%.
• Net margin: 20.83%.
• Average annual earnings growth: 6.1% (company) vs. -3.7% (Chemicals industry).

Primary contributors to the improved profitability:

• Revenue increase (volume and pricing) leading to higher top-line and operating leverage.
• Margin expansion from cost control and improved product mix.
• EPS benefit from both higher net income and stable share count.

Items investors should monitor:

• Sustainability of revenue growth and pricing environment.
• Maintenance of margins amid raw material or energy cost fluctuations.
• Capital allocation impacting ROE (dividends, buybacks, capex).

For broader context on the company's strategic positioning and values, see: Mission Statement, Vision, & Core Values (2026) of Xi'an Manareco New Materials Co.,Ltd.

Xi'an Manareco New Materials Co.,Ltd (688550.SS) - Debt vs. Equity Structure

• Total assets (Q1 2025): CNY 3.434 billion (+4.98% YoY).
• Debt-to-equity ratio: not specified in available sources.
• Equity control: contested-ownership shifts and governance votes have influenced control dynamics.

• May 2024: Kaikang Group purchased shares with intentions to shift control - introduces strategic ownership pressure.
• Mar 31, 2025: Zhuoshih Partners holds 12.3%, the largest single disclosed stake - a focal point in control negotiations.
• May 2025: Shareholder vote rejected abolishing the supervisory board, underscoring governance friction and structural resistance to board changes.
• Ongoing: Equity disputes have complicated clear delineation of control and may influence capital-raising, board decisions, and creditor confidence.

Xi'an Manareco New Materials Co.,Ltd (688550.SS) - Liquidity and Solvency

As of Q1 2025, Xi'an Manareco New Materials Co.,Ltd (688550.SS) demonstrates a liquidity profile supported by sizable cash reserves alongside working capital components and ongoing strategic investments.

• Cash and cash equivalents: CNY 807 million (Q1 2025)
• Accounts receivable: CNY 275 million (Q1 2025)
• Inventory: CNY 484 million (Q1 2025)
• Solvency ratio: not specified in available sources

Key liquidity observations and near-term solvency considerations:

• Strong cash cushion: CNY 807 million provides operational flexibility and buffers short-term obligations.
• Working capital mix: combined receivables and inventory total CNY 759 million, implying active capital tied in operations.
• Project write/termination impact: the termination of the Active Pharmaceutical Ingredient (API) project at Weinan Manareco Pharmaceutical Co., Ltd. in July 2025 follows CNY 179 million invested through June 30, 2025; potential impairment or restructuring effects should be monitored in subsequent financial statements.
• Solvency data gap: absence of a published solvency ratio (e.g., debt-to-equity or interest coverage) requires investors to review balance sheet debt levels and off-balance exposures in filings for a full solvency assessment.
• Ongoing strategic investments: management continues to allocate capital to strategic initiatives, including pharmaceutical-related projects, affecting both short-term liquidity usage and long-term asset base.

For context on company direction and strategic priorities, see: Mission Statement, Vision, & Core Values (2026) of Xi'an Manareco New Materials Co.,Ltd.

Xi'an Manareco New Materials Co.,Ltd (688550.SS): Valuation Analysis

Key market valuation metrics for Xi'an Manareco New Materials Co.,Ltd (688550.SS) indicate a company priced with moderate investor expectations-neither deeply discounted nor richly valued relative to peers in specialty materials. The headline figures below provide a snapshot of how the market currently prices earnings, sales and net assets.

• Trailing P/E: 22.67 - investors are paying CNY 22.67 for each CNY 1 of last-twelve-months earnings.
• Forward P/E: 24.25 - the market is pricing in slightly higher multiple on forecasted earnings, implying modest earnings growth expectations or risk premium.
• P/S ratio: 4.69 - market values the company at about 4.7 times annual sales.
• P/B ratio: 2.52 - market values net assets at roughly 2.5x book value, signaling moderate premium to net asset base.
• Enterprise Value (EV): CNY 6.75 billion - enterprise-level valuation capturing debt and cash effects.
• Market Capitalization: CNY 7.81 billion - total equity market value.

• EV vs Market Cap: EV (CNY 6.75B) being below market cap (CNY 7.81B) can reflect net cash position or low net debt - useful when calculating EV/EBITDA.
• Relative stance: P/E in the low-to-mid 20s positions the stock as neither deep value nor high-growth premium; suitable for investors seeking exposure to materials with moderate expectations.
• Risk considerations: A forward P/E higher than trailing suggests forecast sensitivity-earnings misses could lead to de-rating; conversely, upside from execution or stronger demand could justify a higher multiple.

For additional background on corporate history, ownership and business model, see: Xi'an Manareco New Materials Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Xi'an Manareco New Materials Co.,Ltd (688550.SS) - Risk Factors

• Corporate governance and control disputes: ongoing disagreements over board composition and management decisions have created execution risk and potential legal costs.
• Project termination impact: the formal termination of the company's pharmaceutical project removes an anticipated future revenue stream and reduces diversification.
• Financial structure opacity: key leverage metrics such as a clear debt-to-equity ratio are not publicly specified, raising uncertainty about balance-sheet risk and refinancing needs.
• High industry competition: margins face pressure from domestic and international chemical-materials peers, including larger integrated producers with scale advantages.
• Regulatory risk: evolving environmental, safety and chemical-specific regulations in China and export markets could force capital-intensive upgrades or limit product lines.
• Input-price volatility: swings in petrochemical and specialty-chemicals feedstock prices (e.g., aromatics, olefins, specialty monomers) create earnings variability.

• Short-term liquidity risk: absent clear cash and credit metrics, investors should assume possible pressure if revenue declines or capex needs surge (e.g., regulatory retrofit costs).
• Concentration risk: termination of the pharma project increases reliance on core specialty-materials product lines-sales concentration to a few large customers would heighten counterparty risk.
• Event risk from regulatory change: sudden environmental enforcement or export controls could lead to production halts or costly compliance investments.
• Market-price exposure: profitability is sensitive to raw-material cost fluctuations and finished-goods price competition; margins may compress rapidly in downcycles.

Xi'an Manareco New Materials Co.,Ltd (688550.SS) - Growth Opportunities

• Strategic distributor alliances: established partners across Asia and Europe providing immediate channel access and faster commercialization for specialty polymer and advanced materials products.
• R&D commitment: CNY 200 million earmarked for R&D to accelerate product upgrades, cost-in-use reductions, and differentiated downstream applications.
• Policy tailwinds: national and provincial green-technology incentives offering grants, preferential loans, and tax breaks that reduce effective project returns' hurdle rates.
• Portfolio refocus: termination of the pharmaceutical project frees up working capital and management attention for higher-margin industrial and environmental projects.
• Market expansion: targeted entry into energy storage, EV supply chain components, and EU green-materials programs with premium pricing potential.

• Revenue levers: upselling higher-margin specialty grades, scaling volume via distributor channels, and new product introductions supported by the CNY 200M R&D pipeline.
• Margin upside: process improvements and product mix shift toward premium applications could lift gross margin by 2-4 percentage points if scale targets are met.
• Capital redeployment: funds and human capital from the terminated pharmaceutical effort can accelerate commercialization of projects with projected IRRs in the mid-to-high teens.
• Risk mitigants: diversified distributor base reduces single-market concentration; government support lowers funding costs and shortens payback for green projects.